Orlando, Fla.—Patients with metastatic renal cell carcinoma (mRCC) who respond to programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) checkpoint inhibitor therapy can have persistent clinical benefit, even after treatment discontinuation for immune-related adverse events (irAEs), according to a recent retrospective study. The study challenges the standard of continuing immune checkpoint inhibitors until disease progression or intolerable toxicity.
The analysis, conducted at five